Antibody Drug Conjugate – Molecule Synthesis
We have prepared >20,000 ADC molecules. In addition, we have scaled up hundreds of grams of ADC candidate compounds for further studies.
- Considerable experience in the synthesis of novel payloads and their analogs.
- Large collection of frequently used linkers in house, including PEG linkers, alkyl linkers, click chemistry linkers, and rigid linkers.
- We have also assembled a collection of over 30 series of attachment sites.


Antibody-Drug Conjugate (ADC) Development Services
Antibody Drug Conjugate-related Platform for Preclinical Research
WuXi Biology provides ADC-based in vitro assays and in vivo models:
- Target validation and antibody binding assay
- Antibody internalization assay
- Cell viability assay
- Bystander killing assay
- ADCC and ADCP assay
- CDX and PDX models covering multiple targets (HER2, CLDN18.2, CD30, CD33, BCMA, Trop-2, CD79b, Nectin-4)
- Check out our panel of Enhertu Resistant Tumor Models by clicking HERE
Antibody Drug Conjugate-related in vitro assays
Target validation and antibody binding assay

Cell viability assay_SK-BR-3

Antibody internalization assay

Bystander Killing Assay
Bystander killing occurs when the drug from an ADC is released either from the target cell following
internalization and degradation of the ADC or release of the drug within the extracellular space.


Antibody-dependent cell-mediated phagocytosis (ADCP)
- Effector: Macrophage isolated from PBMC of healthy donor
- Target: SK-BR-3 cell line, labeled with 50 nM CellTrace Violet
- E:T= 8:1

Cell Cycle

Cell Apoptosis

in vivo testing of Antibody Drug Conjugates
WuXi Biology provides CDX and PDX models covering multiple targets:
HER2related in vivo models
Cancer type | 10 models available | Tumor growth curve |
Breast Cancer | HCC1954, MDA-MB-468 , BT474 , etc. | Yes |
Gastric Cancer | NCI-N87, ST-02-0074 , ST-02-0077, etc. | Yes |
Ovarian Cancer | SKOV-3 | Yes |
CLDN18.2 related CDX model
Cancer type | Model ID | Tumor growth curve |
Gastric Cancer | NUGC4 | Yes |
Engineered cell line/model overexpressing hCLDN18.2
Cancer type | Model ID | Tumor growth curve |
Pancreatic Cancer | CLDN18.2 /MIA PaCa-2, xCLDN18.2 /MIA PaCa-2 | Yes |
Pancreatic Cancer | CLDN18.2 /BxPC3 | on going |
Gastric Cancer | CLDN18.2 /NCI-N87 | on going |
CLDN18.2 related PDX models with CLDN18 overexpression
Cancer type | 13 models available | Tumor growth curve |
Pancreatic Cancer | PC-07-0004, PC-07-0033, PC-07-0044, etc. | Yes |
Gastric Cancer | ST-02-0079, ST-02-0318, ST-02-0328, etc. | Yes |
BCMA related CDX models
Cancer type | 10 models available | Tumor growth curve |
Myeloma | NCI-H929, OPM-2, MOLP-8, MM.1S, etc. | Yes |
Lymphoma | Pfeiffer, SU-DHL-6, etc. | Yes |
CD79b related CDX models
Cancer type | 12 models available | Tumor growth curve |
Lymphoma | DAUDI, NAMALWA, RAJI, SU-DHL-4, etc. | Yes |
CD19 related lymphoma CDX models
Cancer type | 15 models available | Tumor growth curve |
Lymphoma | DAUDI, NAMALWA, RAJI, SU-DHL-4, etc. | Yes |
CD22 related lymphoma CDX models
Cancer type | 13 models available | Tumor growth curve |
Lymphoma | DAUDI, NAMALWA, RAJI, SU-DHL-4, etc. | Yes |
CD37 related lymphoma CDX models
Cancer type | 18 models available | Tumor growth curve |
Lymphoma | DAUDI, NAMALWA, RAJI, SU-DHL-4, etc. | Yes |
CD30 related CDX models
Cancer type | Model ID | Tumor growth curve |
Lymphoma | HUT78, SU-DHL-1 | Yes |
Liver cancer | JHH7 | Yes |
Lung cancer | NCI-H211, NCI-H460 | Yes |
CD33 related a CDX models
Cancer type | Model ID | Tumor growth curve |
Lymphoma | U937, RL, DOHH2 | Yes |
Thyroid cancer | FTC-238 | Yes |
Brain cancer | U118MG, U87MG | Yes |
Trop-2related TNBC/bladder cancer/pancreas cancer CDX models
Cancer type | 19 models available | Tumor growth curve |
Breast cancer | HCC70, MDA-MB-468, HCC1937, etc. | Yes |
Bladder cancer | VMCUB1, HT1376, RT112, HT1197, etc. | Yes |
Pancreas cancer | BxPC-3, Panc02.13, HPAC, CAPAN-1, etc. | Yes |
Nectin-4related bladder/ breast/pancreas cancer CDX models
Cancer type | 13 models available | Tumor growth curve |
Breast cancer | HCC70, BT474, HCC1937, MCF-7, etc. | Yes |
Bladder cancer | HT1376, VMCUB1, HT1197, etc. | Yes |
Pancreas cancer | BxPC-3, PANC04.03, CFPAC-1, etc. | Yes |
FOLR1 related ovarian/ breast cancer CDX models
Cancer type | Model ID | Tumor growth curve |
Breast Cancer | T47D, CAL51, HCC1937 | Yes |
Ovarian cancer | OV90, SKOV3, OVCAR3 | Yes |
FOLH1related prostate cancer CDX models
Cancer type | Model ID | Tumor growth curve |
Prostate cancer | 22RV1, VCAP, LNCap | Yes |
Related Resources View All
Isogeneic Trop-2 Model for Evaluating Anti-Trop-2 ADCs
Resource Type: Latest Science Poster
Development of Novel ADC-Resistant Models
Resource Type: Latest Science Poster
AACR 2025 Posters: Sneak Peek
Resource Type: Article Blog
Therapeutic Potential of Polatuzumab Vedotin for the Treatment of DLBCL
Resource Type: Latest Science Poster
Developing Resistant Models to Diverse ADC Drugs
Resource Type: Latest Science Poster
Targeting FAK Improves the Tumor Uptake of ADCs
Resource Type: Latest Science Publication